Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-100 plus doxorubicin versus doxorubicin alone in first-line advanced soft tissue sarcoma
2024-510877-67-00Phase 2Completed
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS), leiomyosarcoma (LMS) and Malignant Fibrous Histiocytoma (MFH) comparing LB-100 + doxorubicin with Doxorubicin alone (2 arms). Started May 2024; status: completed.
02
Drugs
LB-100doxorubicin
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)Malignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on 2024-510877-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510877-67-00.